The U.S. Food and Drug Administration on Friday approved expanded use of Yescarta, a cell therapy made by Gilead Sciences Inc's Kite unit, as a first option after chemotherapy for adults with an advanced, aggressive form of blood cancer.
Gilead Sciences Inc pharmaceutical company is seen after they announced a Phase 3 Trial of the investigational antiviral drug Remdesivir in patients with severe coronavirus disease , during the outbreak of the coronavirus disease , in Oceanside, California, U.S., April 29, 2020. REUTERS/Mike BlakeApril 1 - The U.S.
Yescarta is part of a class of treatments known as CAR-Ts, which involve taking immune system blood cells from a patient, shipping them to a plant to be re-engineered to better fight certain cancers and then returning them to the patient.The FDA's decision will increase to around 14,000 from 8,000 the number of lymphoma patients eligible for the therapy, Christi Shaw, Kite's chief executive, told Reuters last month in Philadelphia at"Current standard of care is a difficult process.
The FDA said the drug's label warns of a serious complication associated with CAR-T therapy called cytokine release syndrome, which can cause a range of dangerous symptoms including fever and neurological problems.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
FDA panel narrowly sides against experimental ALS drugFederal health advisers on Wednesday narrowly ruled against an experimental drug for the debilitating illness known as Lou Gehrig’s disease, a potential setback for patient groups who have lobbied for the medication’s approval.
Consulte Mais informação »
FDA panel narrowly sides against experimental ALS drugU.S. health advisers have narrowly ruled against an experimental drug for the debilitating illness known as Lou Gehrig’s disease.
Consulte Mais informação »
New ALS drug fails to win FDA panel recommendationCommittee members, who voted 4-6 against Amylyx Pharmaceuticals' drug, said the decision was difficult, given the lack of treatments available for the fatal disease.
Consulte Mais informação »
FDA Authorizes Second COVID-19 Booster Shots for Some Adults—Experts Explain EligibilityFDA Authorizes a Second COVID-19 Booster Shot for Adults Over 50
Consulte Mais informação »
FDA clears second COVID booster for adults 50+, questions remainIn the fight against the pandemic, the Food and Drug Administration authorized a new round of Moderna and Pfizer COVID-19 vaccines for adults who are 50 or over.
Consulte Mais informação »